Navidea Biopharmaceuticals, Inc. Share Price
Equities
NAVB
US63937X2027
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0381 USD | +1.33% | +8.86% | -30.98% |
Sales 2021 | 532K 44.32M | Sales 2022 | 65.65K 5.47M | Capitalization | 6.78M 565M |
---|---|---|---|---|---|
Net income 2021 | -11M -917M | Net income 2022 | -15M -1.25B | EV / Sales 2021 | 50.2 x |
Net cash position 2021 | 3.48M 290M | Net Debt 2022 | 440K 36.67M | EV / Sales 2022 | 110 x |
P/E ratio 2021 |
-2.5
x | P/E ratio 2022 |
-0.38
x | Employees | 13 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 64.11% |
1 day | +1.33% | ||
1 week | +8.86% | ||
Current month | +4.38% | ||
1 month | +5.54% | ||
3 months | -33.74% | ||
6 months | -26.73% | ||
Current year | -30.98% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Dais
DFI | Director of Finance/CFO | 58 | 28/23/28 |
Michael Blue
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Richard McFerron
LAW | General Counsel | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joshua Wilson
BRD | Director/Board Member | 47 | 30/22/30 |
John Scott
BRD | Director/Board Member | 69 | 08/21/08 |
Jill Stefanelli
BRD | Director/Board Member | 46 | 01/23/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.0381 | +1.33% | 2,796 |
25/24/25 | 0.0376 | +0.27% | 15,041 |
24/24/24 | 0.0375 | +1.90% | 3,138 |
23/24/23 | 0.0368 | -16.36% | 6,635 |
22/24/22 | 0.044 | +25.71% | 55,172 |
Delayed Quote OTC Markets, April 26, 2024 at 10:38 pm IST
More quotes1st Jan change | Capi. | |
---|---|---|
-30.98% | 3.81M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NAVB Stock